Zyrova Indications/Uses

5 mg: Hyperlipidemia and Mixed Dyslipidemia: Used to reduced LDL cholesterol, apolipoprotein B, and triglycerides, and to increase HDLcholesterol in the management of hyperlipidemias, including primary hypercholesterolaemia (type lla), mixed dyslipidaemia (type llb), and Hypertriglyceridemia (type IV), as well as in patients with homozygous familial hypercholesterolaemia.
It is also used to reduce the progression of atherosclerosis.
Homozygous Familial Antihyperlipidemic: Rosuvastatin is indicated as adjunctive therapy to the lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C Total-C. and ApoB in adult patients with homozygous familial hyperlipidemia.
Slowing of the progression of the atherosclerosis: Rosuvastatin is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients is a part of a treatment strategy to lower Total-C and V dyslipidemias.
Limitations of use: The effect of Rosuvastatin on cardiovascular morbidity and mortality has not been determined.
Rosuvastatin has not been studied in Fredrickson Type I, III, and V dyslipidemias.
10 mg & 20 mg: Patients suffering from primary hypercholesterolemia (type IIa indicating homozygous familial hypercholesterolemia) or mixed dyslipidemia (type IIb) or in patients suffering from homozygous familial hypercholesterolemia as an adjunct to diet when response to diet and other non-pharmacological treatments (eg, exercise, weight reduction) is inadequate.
40 mg: Hyperlipidemia and Mixed Dyslipidemia: Rosuvastatin is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate.
Pediatric Patients 10 to 17 years of age with Heterozygous Familial Hypercholesterolemia (HeFH): Adjunct to diet to reduce Total-C, LDL-C, and ApoB levels in adolescent boys and girls, who are at least one year postmenarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C> 190 mg/dl or >160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.
Hypertriglyceridemia: Rosuvastatin is indicated as an adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia.
Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia): Rosuvastatin is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia).
Homozygous Familia Hypercholesterolemia: Rosuvastatin is indicated as adjunctive therapy to other lipid-lowering treatments (e.g. LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia.
Slowing of the Progression of Atherosclerosis: Rosuvastatin is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.
Primary Prevention of Cardiovascular Disease: In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age>50 years old in men and > 60 years old in women, hsCRP > 2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease, Rosuvastatin is indicated to: reduce the risk of stroke, reduce the risk of myocardial infarction, reduce the risk of arterial revascularization procedures.
Limitations of Use: Rosuvastatin has not been studied in Fredrickson Type I and V dyslipidemias.